別品名 |
NVP-BEZ235, Dactolisib
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
469.54
|
CAS RN® |
915019-65-7
|
化合物の概要 |
PI3K and mTOR inhibitor.
|
構造 |
C30H23N5O
|
溶媒 |
DMF18 mg/mL warmed (38.33 mM)DMSO0.01 mg/mL (0.02 mM)WaterInsoluble
|
使用目的 |
BEZ235 inhibits PI3K and mTORC1/2, exhibiting anticancer chemotherapeutic activity. In nasopharyngeal cancer cells, BEZ235 induces G1 phase cell cycle arrest and apoptosis; in similar animal models of nasopharyngeal or cholangiocarcinoma, this compound inhibits tumor growth. BEZ235 also induces apoptosis in hepatocellular carcinoma cells, also potentially inducing autophagy.
|
参考文献 |
Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2014 Feb 1;343(1):24-32. PMID: 24041865.Yothaisong S, Dokduang H, Techasen A, et al. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 2013 Dec;34(6):3637-48. PMID: 23832540.Chang Z, Shi G, Jin J, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med. 2013 Jun;31(6):1449-56. PMID: 23588698.
|
|
メーカー |
品番 |
包装 |
LKT
|
B1996
|
25 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
法規制 |
劇
|
保存温度 |
-20℃
|
|